All Episodes

NEJM Interview: Lena Makaroun on opportunities for clinicians to address firearm-related risks with their older patients.

NEJM Interview: Sarah Schmitz on protections for people enrolled in trials of investigational agents for obesity.

NEJM Interview: Benjamin Scher on opioid litigation and governance systems for spending related funds.

NEJM Interview: Christopher Forrest on declines in the health of U.S. children and the role of communities in reversing those trends.

NEJM Interview: Dhruv Khullar on concerns about displacement of clinicians by artificial intelligence and counterarguments based on economic theory.

NEJM Interview: Elizabeth Kaplan on changes to the U.S. Preventive Services Task Force and the importance of evidence-based recommendations for preventive services.

NEJM Interview: Elizabeth Tobin-Tyler on the legal argument that permitting telehealth access to mifepristone can abet reproductive coercion.

NEJM Interview: Rebecca Haffajee on the rescheduling of medical marijuana products and its potential effect on research.

NEJM Interview: Eric Schneider on the limitations of pay-for-performance programs and alternative options to support quality improvement.

NEJM Interview: Jean Nachega on the importance of investment in equitable partnerships, community trust, and local scientific leadership for outbreak preparedness.

NEJM Interview: Jerry Avorn on the role of litigation in addressing product-related damage to health.

NEJM Interview: Arnold Monto on the value and feasibility of various methods for evaluating the protection offered by vaccines.

NEJM Interview: Yaara Zisman-Ilani on navigating the uncertainty surrounding medication management in autism care.

NEJM Interview: Mark Unruh on projected increases in the need for long-term services and supports in the United States amid declines in nursing-home capacity.

NEJM Interview: Justin Barr on physician leadership in American society and politics over the past 250 years.

NEJM Interview: Stacie Dusetzina on a new program that will allow Medicare Part D enrollees to obtain GLP-1 medications for use for weight loss.

NEJM Interview: Marcus Hughes on inconsistent oversight of psychedelic agents at the state and federal levels in the United States.

NEJM Interview: Edward Ryan on factors driving continued disease and death from cholera and opportunities for progress.

NEJM Interview: Loren Adler on regulatory strategies for addressing factors that make consolidation in health care especially profitable.

NEJM Interview: Deirdre Tobias on the 2025–2030 Dietary Guidelines for Americans, including areas of confusion and contradiction.

NEJM Outbreaks Updates — Andes Hantavirus

NEJM Interview: Raja-Elie Abdulnour on the need for clinicians and AI systems to refrain from expressing undue confidence in their knowledge.

NEJM Interview: Jatin Vyas on the effect of corporatization of academic medical centers on medical education and trainee development.

NEJM Interview: Amanda Banks on concerns about a potential association between GLP-1 receptor agonists and restrictive eating disorders.

Introducing: Intention to Treat — Season 2

NEJM Interview: Sara Gerke on a Utah pilot program involving an AI system that autonomously renews certain prescriptions.

NEJM Interview: Amy Stimpfel on a new policy that would cap loans for graduate nursing and other students.

NEJM Interview: Danielle Jones on the development of tools to help family physicians address social determinants of health and advance health equity.

NEJM Interview: Lawrence Casalino on qualities of corporate organizations that could affect physicians’ intrinsic motivation and the quality of the care they provide.

NEJM Interview: Douglas Opel on the importance of clinician–parent communication amid changes to the childhood vaccine schedule.

NEJM Interview: Abbas Hassan on the gap between the services that residents and fellows provide and the revenue that hospitals can capture.

NEJM Interview: Ruqaiijah Yearby on recent trends in health care markets and their implications for health equity.

NEJM Interview: Bruce Chabner on recent FDA statements regarding potential uses for leucovorin.

NEJM Interview: Sonja Rasmussen on the 2025–2026 influenza season, including factors contributing to the intensity of influenza activity.

NEJM Interview: Carmel Shachar on the opportunities and risks presented by the Rural Health Transformation Program.

NEJM Interview: Leemore Dafny on the implications of corporatization of the U.S. health insurance industry.

NEJM Interview: Robert Kocher on strategies for improving blood-pressure control in the United States.

NEJM Interview: Tara Eicher on changes in autism diagnosis in recent years and statements from the federal government regarding autism.

NEJM Interview: Tara Sklar on U.S. telehealth payment policy and the potential for a revised approach to support competition and efficiency.

NEJM Interview: Rachel Sachs on recent agreements governing coverage and pricing of GLP-1 receptor agonists in the United States.

NEJM Interview: Ambar La Forgia on the drivers and effects of corporatization of outpatient medical services.

NEJM Interview: Anne Zink on increases in rates of congenital syphilis and potential strategies for reversing this trend.

NEJM Interview: Reshma Ramachandran on changes to the FDA’s adverse-event data releases and future directions for enhancing its safety-surveillance infrastructure.

NEJM Interview: Robert Huckman on the dearth of successful business models aimed at keeping people healthy.

NEJM Interview: Nishant Uppal on the emergence of venture capital investing by academic medical centers and its potential implications.

NEJM Interview: Jane Zhu on a new Oregon law that aims to address corporate control in medicine.

NEJM Interview: Joshua Barocas on recent federal actions related to harm-reduction programs for people with substance use disorders.

NEJM Interview: Yashaswini Singh on antitrust enforcement as a potential counterbalance to consolidation resulting from rapid health care corporatization.

NEJM Interview: Eberechi Nwogu-Onyemkpa on integrating palliative care services and resources into the management of sickle cell disease.

NEJM Interview: Michael Liu on a new model that will expand the use of prior authorization in traditional Medicare.

NEJM Interview: Andrew Gabrielson on cuts to the U.S. research agency charged with safeguarding workers’ health.

NEJM Interview: Steven Lipstein on the drivers and the benefits of mergers and consolidation, from the perspective of a health care system leader.

NEJM Interview: Nancy Krieger on the effects of structural racism on health and health care and the conflation of research on health equity with DEI work.

NEJM Interview: John Ayanian on opportunities to study the health and economic effects of Medicaid work requirements and to mitigate their adverse consequences.

NEJM Interview: Darshali Vyas on campaigns to remove race from clinical algorithms.

NEJM Interview: Amanda Janitz on a navigation program aimed at improving cancer outcomes for American Indian and Alaska Native patients.

NEJM Interview: Amitabh Chandra on why corporatization occurs in health care, when it can succeed, and why it can go wrong.

NEJM Interview: Nicholas Bagley on the Supreme Court’s decision in a case with implications for coverage of preventive services.

NEJM Interview: Tom Frieden on the role of the CDC and current threats to the U.S. public health infrastructure.

NEJM Interview: Nancy Tomes on the century-long transition to a corporate business model in U.S. health care.

NEJM Interview: Rohan Khazanchi on the gradual but incomplete shift to race-free equations for interpreting pulmonary function tests.

NEJM Interview: Jason Schwartz on changes to the Advisory Committee on Immunization Practices and approaches to sustaining U.S. vaccination efforts.

NEJM Interview: Katie Watson on the interaction of abortion laws with advance-directive and end-of-life laws.

NEJM Interview: Peter Marks on the disruption of traditional approaches to establishing Covid-19 vaccine policy in the United States.

NEJM Interview: Patricia Mae Santos on the effects of U.S. anti-immigrant policies on immigrant health care workers and their patients.

NEJM Interview: Erin Fuse Brown on the manifestations and effects of corporatization in health care.

NEJM Interview: Dariush Mozaffarian on the health harms of ultraprocessed foods and related policy actions.

NEJM Interview: I. Glenn Cohen on the professional implications of the use of artificial-intelligence–based monitoring systems in medicine.

NEJM Interview: Amanda Kallen on the history of women’s health research and recent actions that are jeopardizing progress in women’s health.

NEJM Interview: David Jones on the disparate historical approaches to anemia diagnosis and their lessons for physicians.

NEJM Interview: Amar Kelkar on NIH indirect-cost coverage and U.S. medical research.

NEJM Interview: Zirui Song on the rise of concierge and direct primary care practices in the United States.

NEJM Interview: Alice Chen on responding to the U.S. administration’s threats to health and physicians’ values and maintaining hope in difficult times.

NEJM Interview: Christopher Duggan on the effects of ending U.S. foreign-assistance and global health programs.

NEJM Interview: Arthur Robin Williams on alcohol consumption in the United States and the effects of alcohol taxes.

NEJM Interview: Lauren Jatt on the efficacy of twice-yearly lenacapavir for preexposure prophylaxis and its implications for the development of an HIV vaccine.

NEJM Outbreaks Updates — H5N1 in Indiana

NEJM Interview: Patricia Zettler on a proposed FDA rule on nicotine yields and potential challenges moving forward.

NEJM Interview: John Patrick Co on a stipend program designed to address cost-of-living concerns for residency applicants.

NEJM Interview: Rochelle Walensky on the increased workload and emotional and financial burden associated with applying to medical school.

NEJM Interview: Erin Fuse Brown on telehealth arrangements that have prompted concerns about inappropriate prescribing and unnecessary spending.

NEJM Interview: Alex Keuroghlian on responding to policy threats to protections for transgender and nonbinary people.

NEJM Outbreaks Update — H5N1: A View from the States

NEJM Interview: Sara Gerke on the potential for genetic data and other personal information to be included in business transactions in the United States.

NEJM Outbreaks Update — H5N1

NEJM Interview: John Kelly on shifts in approaches for addressing substance use disorder.

NEJM Interview: Peter Ubel on strategies for protecting patients from high out-of-pocket costs for drugs with questionable benefits.

NEJM Interview: Yashaswini Singh on the expansion of private equity investments in health care and actions to safeguard patient interests in various countries.

NEJM Interview: Joseph Ross on the newly implemented Cell and Gene Therapy Access Model.

NEJM Interview: Daniel Aaron on a Supreme Court case about e-cigarettes that could have implications for the FDA’s authority and for public health.

NEJM Interview: Craig Spencer on the need for action to address persistent inequities in global health.

NEJM Interview: Carmel Shachar on modernizing labor laws and strike regulations to support physicians, patients, and hospitals.

NEJM Interview: David Velasquez on care for older, low-income adults who can’t enroll in Medicare or Medicaid because they’re undocumented immigrants.

NEJM Interview: Joey Mattingly on providing widespread access to HCV treatment at the lowest possible price.

NEJM Interview: Lauren Schiff on the need for improved training and increased comfort in treating autistic people.

NEJM Interview: Bindu Kanapuru on the FDA’s new expedited withdrawal procedure for accelerated approvals.

NEJM Interview: Karen Joynt Maddox on the Transforming Episode Accountability Model recently announced by CMS.

NEJM Interview: Andrew Hantel on a source of discrimination against some patients in cancer research and care practices.

NEJM Interview: Benjamin Rome on the results of the initial round of drug-price negotiation under the Inflation Reduction Act.

NEJM at AHA — Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease